Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Arterial Hypertension

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    690 result(s) found for: Arterial Hypertension. Displaying page 13 of 35.
    «« First « Previous 9  10  11  12  13  14  15  16  17  Next» Last»»
    EudraCT Number: 2010-019883-36 Sponsor Protocol Number: CAMN107X2201 Start Date*: 2010-08-31
    Sponsor Name:Novartis Pharma AG
    Full Title: A 24 week, randomized, double blind, multicenter, placebo-controlled efficacy, safety, tolerability and PK trial of Nilotinib (Tasigna®, AMN107) in Pulmonary Arterial Hypertension (PAH)
    Medical condition: Pulmonary Arterial Hypertension (PAH) Class II or III patients remaining symptomatic despite at least one PAH-specific therapy.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10064911 Pulmonary arterial hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) IT (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-000165-12 Sponsor Protocol Number: RLY5016-205 Start Date*: 2011-05-27
    Sponsor Name:Relypsa, Inc.
    Full Title: A Multicenter, Randomized, Open-Label, Dose Ranging Study to Evaluate the Efficacy and Safety of RLY5016 in the Treatment of Hyperkalemia in Patients with Hypertension and Diabetic Nephropathy Rece...
    Medical condition: Hyperkalemia in Patients with Hypertension and Diabetic Nephropathy
    Disease: Version SOC Term Classification Code Term Level
    13.1 10047065 - Vascular disorders 10020772 Hypertension PT
    13.1 10027433 - Metabolism and nutrition disorders 10020647 Hyperkalemia LLT
    13.1 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Prematurely Ended) AT (Prematurely Ended) SI (Completed)
    Trial results: View results
    EudraCT Number: 2015-000645-23 Sponsor Protocol Number: Borealis1 Start Date*: 2015-06-19
    Sponsor Name:CIBER (Centro de Investigacion Biomedica en Red)
    Full Title: Safety, tolerability and efficacy of nocturnal hypertension treatment with domperidone in the sleep apnea-hypopnea syndrome. Pilot study.
    Medical condition: Nocturnal hypertension in the sleep apnea-hypopnea syndrome.
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004855 10040976 Sleep apnea syndrome LLT
    17.1 100000004866 10019180 HBP LLT
    Population Age: Adults Gender: Male
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-005886-78 Sponsor Protocol Number: B1321002 Start Date*: 2010-01-12
    Sponsor Name:Pfizer Ltd.
    Full Title: A PHASE 3, MULTI-CENTER, OPEN LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY OF MONOTHERAPY SITAXSENTAN SODIUM AND COMBINATION THERAPY WITH SITAXSENTAN SODIUM AND SILDENAFIL CITRATE IN SUBJECTS WITH ...
    Medical condition: PULMONARY ARTERIAL HYPERTENSION
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037401 Pulmonary hypertensions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) SK (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-003042-27 Sponsor Protocol Number: APD811-007 Start Date*: 2015-04-23
    Sponsor Name:United Therapeutics Corporation
    Full Title: An Open-Label Extension Study of APD811-003 in Patients with Pulmonary Arterial Hypertension
    Medical condition: Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) ES (Ongoing) PL (Completed) RO (Ongoing) SK (Completed)
    Trial results: View results
    EudraCT Number: 2005-001967-70 Sponsor Protocol Number: AC-052-367 Start Date*: 2005-10-13
    Sponsor Name:Actelion Pharmaceuticals Ltd.
    Full Title: An open-label, long-term, safety, and tolerability extension study using the pediatric formulation of bosentan in the treatment of children with idiopathic or familial pulmonary arterial hypertensi...
    Medical condition: Idiopathic or familial pulmonary arterial hypertension
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-002314-21 Sponsor Protocol Number: MEN IFR/08/NEB-HYP/01 Start Date*: 2008-05-23
    Sponsor Name:A. MENARINI I.F.R.
    Full Title: VALUTAZIONE COMPARATIVA DEGLI EFFETTI SULLA FUNZIONE ENDOTELIALE DEL TRATTAMENTO CON NEBIVOLOLO E IDROCLOROTIAZIDE VS IRBESARTAN E IDROCLOROTIAZIDE IN PAZIENTI CON IPERTENSIONE ARTERIOSA NEO-DIAGNO...
    Medical condition: IPERTENSIONE ARTERIOSA
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015488 Essential hypertension LLT
    9.1 10047065 Vascular disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-005157-63 Sponsor Protocol Number: AC-052-365 Start Date*: 2005-06-15
    Sponsor Name:Actelion Pharmaceuticals Ltd.
    Full Title: An open label, multicenter study to assess the pharmacokinetics, tolerability, and safety of a pediatric formulation of bosentan in children with idiopathic or familial pulmonary arterial hypertens...
    Medical condition: Idiopathic or familial PAH
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-002469-11 Sponsor Protocol Number: CSPP100A2403 Start Date*: 2008-05-13
    Sponsor Name:Novartis Farmaceutica S.A.
    Full Title: Estudio aleatorizado, doble ciego, de grupos paralelos, multicéntrico, para comparar la eficacia y seguridad de aliskiren 300 mg administrado una vez al día y de aliskiren 150 mg administrado dos v...
    Medical condition: Hipertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015488 Essential hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-003921-13 Sponsor Protocol Number: 12/0368 Start Date*: 2013-06-07
    Sponsor Name:University College London
    Full Title: COMbination therapy for PulmonAry hypertension using RacEcadotril (COMPARE).
    Medical condition: Pulmonary hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037400 Pulmonary hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-004631-31 Sponsor Protocol Number: REM-PH-416 Start Date*: 2012-03-13
    Sponsor Name:United Therapeutics Corp.
    Full Title: A 16 Week, Open Label, Multi-Centre, Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of a Rapid Dose Titration Regimen of Subcutaneous Remodulin® Therapy in Subjects with Pul...
    Medical condition: Pulmonary Arterial Hypertension (PAH)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10065151 Idiopathic pulmonary arterial hypertension LLT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10065152 Familial pulmonary arterial hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-001900-17 Sponsor Protocol Number: 2020/0431/HP Start Date*: 2022-10-24
    Sponsor Name:DRCI - CHU de Rouen
    Full Title: PILOT STUDY OF THE EFFECT OF A SUBSTANCE P ANTAGONIST, APREPITANT, ON THE SECRETION OF ALDOSTERONE IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA AND ARTERIAL HYPERTENSION SYNDROME
    Medical condition: Patients with obstructive sleep apnea syndrome with arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10052741 Endocrine and metabolic secondary hypertension HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-010170-38 Sponsor Protocol Number: CSPP100G2301 Start Date*: 2010-07-21
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People Aliskiren Prevention Of Later Life Outcomes (APOLLO)
    Medical condition: cardiovacular disease, fonctional hypertension,
    Disease: Version SOC Term Classification Code Term Level
    12.1 10020772 Hypertension LLT
    12.1 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) HU (Completed) DE (Completed) IE (Prematurely Ended) CZ (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002348-99 Sponsor Protocol Number: AUTH88622 Start Date*: 2014-09-22
    Sponsor Name:Aristotle University Thessaloniki
    Full Title: A randomised, double blind, placebo-controlled study of the effect of liraglutide on arterial blood pressure in hypertensive patients with type 2 diabetes mellitus
    Medical condition: Hypertention, Type 2 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    17.0 10047065 - Vascular disorders 10020772 Hypertension PT
    17.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2009-012966-30 Sponsor Protocol Number: DSE-SEV-02-09 Start Date*: 2009-11-16
    Sponsor Name:DAIICHI SANKYO EUROPE GmbH
    Full Title: “Eficacia de Sevikar® comparado con la combinación de Perindoprilo/Amlodipino sobre la Presión Arterial Central, en Pacientes con Hipertensión moderada a severa - SEVITENSION”
    Medical condition: Eficacia de Sevikar® comparado con la combinación de Perindoprilo/Amlodipino sobre la Presión Arterial Central, en Pacientes con Hipertensión moderada a severa - SEVITENSION
    Disease: Version SOC Term Classification Code Term Level
    9 10015491 Essential hypertension, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-004300-35 Sponsor Protocol Number: ikfe-Lina-003 Start Date*: 2013-01-17
    Sponsor Name:Profil Mainz GmbH & Co KG
    Full Title: Effects of Linagliptin on Endothelial- , Renal-, and Retinal Function in Comparison to Placebo in Patients with Hypertension and Albuminuria
    Medical condition: Linagliptin in Patients with Hypertension and Albuminuria
    Disease: Version SOC Term Classification Code Term Level
    16.1 10038359 - Renal and urinary disorders 10038464 Renal hypertension PT
    16.1 10038359 - Renal and urinary disorders 10001580 Albuminuria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000137-31 Sponsor Protocol Number: 2017-2019 Start Date*: 2017-12-19
    Sponsor Name:VU University Medical Center
    Full Title: Pulmonary Hypertension REversal in Clusters of Patients With Identical Pathobiological Substrates. 6-Mercaptopurine Proof-of-Concept Trial
    Medical condition: Pulmonary arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037454 Pulmonary vascular disorders HLGT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037401 Pulmonary hypertensions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003910-26 Sponsor Protocol Number: 01/2015 Start Date*: 2017-12-11
    Sponsor Name:Núcleo de Estudos de Hipertensão da Beira Interior
    Full Title: Fase II, unicenter, open, randomized trial to evaluate the response of Th17 and T regulatory lymphocytes to 24 weeks supplementation with cholecalciferol in patients with arterial hypertension, obe...
    Medical condition: Obesity associated arterial hypertension Metabolic syndrome associated arterial hypertension
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004579-39 Sponsor Protocol Number: CSPP100A2332 Start Date*: 2006-09-08
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An eight-week, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren / HCTZ (300/12.5 mg and 300/25 mg) in comparison with ...
    Medical condition: Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-004534-24 Sponsor Protocol Number: 2007CV09 Start Date*: 2008-11-18
    Sponsor Name:University of Dundee
    Full Title: Can high-dose vitamin D supplementation reduce blood pressure and markers of cardiovascular risk in older people with isolated systolic hypertension?
    Medical condition: Isolated systolic hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050591 Isolated systolic hypertension LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 9  10  11  12  13  14  15  16  17  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 29 08:41:15 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA